<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0101244649
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FORTEO 20 MCG per 80MCL 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TERIPARATIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1421.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ELI LILLY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ELI LILLY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ELI LILLY NEDERLAND B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H05AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>FORTEO contains the active substance teriparatide that is used to make the bones stronger, and to reduce the risk of fractures by stimulating bone formation.</p><p>FORTEO is used to treat osteoporosis in adults. Osteoporosis is a disease that causes your bones to become thin and fragile. This disease is especially common in women after the menopause, but it can also occur in men. Osteoporosis is also common in patients receiving corticosteroids.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use FORTEO &nbsp;</strong></p><ul><li>if you are allergic&nbsp; to teriparatide or any of the other ingredients of this medicine (listed in section 6).</li><li>if you suffer from high calcium levels (pre-existing hypercalcaemia).</li><li>if you suffer from serious kidney problems.</li><li>if you have ever been diagnosed with bone cancer or other cancers that have spread (metastasised) to your bones.</li><li>if you have certain bone diseases. If you have a bone disease, tell your doctor.</li><li>if you have unexplained high levels of alkaline phosphatase in your blood, which means you might have Paget&rsquo;s disease of bone (disease with abnormal bone changes). If you are not sure, ask your doctor.</li><li>if you have had radiation therapy involving your bones.</li><li>if you are pregnant or breast-feeding.</li></ul><p><strong>Warnings and precautions</strong></p><p>FORTEO &nbsp;may cause an increase in the amount of calcium in your blood or urine.</p><p>Talk to your doctor or pharmacist before or while using FORTEO:</p><ul><li>if you have continuing nausea, vomiting, constipation, low energy, or muscle weakness. These may be signs there is too much calcium in your blood.&nbsp;</li><li>if you suffer from kidney stones or have a history of kidney stones.</li><li>if you suffer from kidney problems (moderate renal impairment).</li><li>If you have or have had too much calcium in your blood (hypercalcemia).</li></ul><p>Some patients get dizzy or get a fast heartbeat after the first few doses. For the first doses, inject FORTEO where you can sit or lie down right away if you get dizzy.</p><p>The recommended treatment time of 24 months should not be exceeded.</p><p>FORTEO should not be used in growing adults.</p><p><strong>Possible bone cancer.</strong> During drug testing, the medicine in FORTEO caused some rats to develop a bone cancer called osteosarcoma. Studies in people have not shown that FORTEO increases your chance of getting osteosarcoma. There is little information about the chance of getting osteosarcoma in patients using FORTEO beyond 2 years.</p><p><strong>Children and adolescents</strong></p><p>FORTEO should not be used in children and adolescents (less than 18 years).</p><p><strong>Other medicines and FORTEO</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, because occasionally they may interact (e.g. digoxin/digitalis, a medicine used to treat heart disease).</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Do not use FORTEO &nbsp;if you are pregnant or breast-feeding. If you are a woman of child-bearing potential, you should use effective methods of contraception during use of FORTEO. If you become pregnant, FORTEO &nbsp;should be discontinued.<u> </u>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>Some patients may feel dizzy after injecting FORTEO. If you feel dizzy you should not drive or use machines until you feel better.</p><p><strong>FORTEO contains sodium :</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you to. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is 20 micrograms given once daily by injection under the skin (subcutaneous injection) in the thigh or abdomen. To help you remember to take your medicine, inject it at about the same time each day.</p><p>Inject FORTEO each day for as long as your doctor prescribes it for you. You should not use FORTEO for more than 2 years over your lifetime unless your healthcare provider finds that you need longer treatment because you have a high chance of breaking your bones.</p><p>FORTEO can be injected at meal times.</p><p>Read the user manual booklet, which is included in the carton for instructions on how to use the FORTEO &nbsp;pen.</p><p>Injection needles are not included with the pen. Becton, Dickinson and Company pen needles can be used.</p><p>&nbsp;</p><p>You should take your FORTEO&nbsp;injection shortly after you take the pen out of the refrigerator as described in the user manual. Put the pen back into the refrigerator immediately after you have used it.</p><p>Use a new injection needle for each injection and dispose of it after each use. Never store your pen with the needle attached. Never share your FORTEO pen with others.</p><p>Your doctor may advise you to take FORTEO with calcium and vitamin D. Your doctor will tell you how much you should take each day.</p><p>FORTEO can be given with or without food.</p><p><strong>If you use more FORTEO &nbsp;than you should</strong></p><p>If, by mistake, you have used more FORTEO than you should, contact your doctor or pharmacist.</p><p>The effects of overdose that might be expected include nausea, vomiting, dizziness, and headache.</p><p><strong>If you forget or cannot take FORTEO at your usual time</strong>, take it as soon as possible on that day. Do not take a double dose to make up for a forgotten dose. Do not take more than one injection in the same day. Do not try to make up for a missed dose.</p><p><strong>If you stop taking FORTEO</strong></p><p>If you are considering stopping FORTEO treatment, please discuss this with your doctor. Your doctor will advise you and decide how long you should be treated with FORTEO.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most common side effects are pain in limb (frequency is very common, may affect more than 1 in 10 people) and feeling sick, headache and dizziness (frequency is common).</p><p>If you become dizzy (light-headed) after your injection, you should sit or lie down until you feel better. If you do not feel better, you should call a doctor before you continue treatment. Cases of fainting have been reported in association with teriparatide use.</p><p>If you experience discomfort such as redness of the skin, pain, swelling, itching, bruising or minor bleeding around the area of the injection (frequency is common), this should clear up in a few days or weeks. Otherwise tell your doctor as soon as possible.</p><p>Some patients may have experienced allergic reactions<u> </u>soon after injection, consisting of breathlessness, swelling of the face, rash and chest pain (frequency is rare). In rare cases, serious and potentially life-threatening allergic reactions including anaphylaxis can occur.</p><p>Other side effects include:</p><p>Common: may affect up to 1 in 10 people</p><ul><li>increase in blood cholesterol levels</li><li>depression</li><li>neuralgic pain in the leg</li><li>feeling faint</li><li>irregular heart beats</li><li>breathlessness</li><li>increased sweating</li><li>muscle cramps</li><li>loss of energy</li><li>tiredness</li><li>chest pain</li><li>low blood pressure</li><li>heartburn (painful or burning sensation just below the breast bone)</li><li>being sick (vomiting)</li><li>a hernia of the tube that carries food to your stomach</li><li>low haemoglobin or red blood cell count (anaemia)</li><li>anxiety</li></ul><p>Uncommon: may affect up to 1 in 100 people</p><ul><li>increased heart rate</li><li>abnormal heart sound</li><li>shortness of breath</li><li>haemorrhoids (piles)</li><li>accidental loss or leakage of urine</li><li>increased need to pass water</li><li>weight increase</li><li>kidney stones</li><li>pain in the muscles and pain in the joints. Some patients have experienced severe back cramps or pain which lead to hospitalisation.</li><li>increase in blood calcium level</li><li>increase in blood uric acid level</li><li>increase in an enzyme called alkaline phosphatase.</li></ul><p>Rare: may affect up to 1 in 1,000 people&nbsp;</p><ul><li>reduced kidney function, including renal failure</li><li>swelling, mainly in the hands, feet and legs.</li></ul><p>Bone cancer (osteosarcoma): Tell your healthcare provider right away if you have pain in your bones, pain in any areas of your body that does not go away, or any new or unusual lumps or swelling under your skin that is tender to touch.&nbsp;</p><p>Adverse Reactions from Postmarketing Spontaneous Reports</p><p>Adverse events reported since market introduction that were temporally related to FORTEO therapy include the following:</p><ul><li>Allergic Reactions: Anaphylactic reactions, drug hypersensitivity, angioedema, and urticaria.</li></ul><p>&nbsp;</p><p><strong>Reporting</strong><strong> of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and pen after EXP. The expiry date refers to the last day of that month.</p><p>FORTEO should be stored in a refrigerator (2&deg;C to 8&deg;C) at all times. You can use FORTEO for up to 28 days after the first injection, as long as the pen is stored in a refrigerator (2&deg;C to 8&deg;C).</p><p>Do not freeze FORTEO. Avoid placing the pens close to the ice compartment of the refrigerator to prevent freezing. Do not use FORTEO if it is, or has been, frozen.</p><p>Each pen should be properly disposed of after 28 days, even if it is not completely empty.</p><p>FORTEO contains a clear and colourless solution. Do not use FORTEO if solid particles appear or if the solution is cloudy or coloured.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What FORTEO contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is teriparatide. Each millilitre of the solution for injection contains 250 micrograms of teriparatide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are glacial acetic acid, sodium acetate (anhydrous), mannitol, metacresol&nbsp;and water for injections. In addition, hydrochloric acid and/or sodium hydroxide solution may have been added for pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FORTEO is a colourless and clear solution. It is supplied in a cartridge contained in a pre-filled disposable pen. Each pen contains 2.4 mL of solution enough for 28 doses. The pens are available in cartons containing one or three pens. Not all pack sizes may be available.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing authorisation holder:</p><p>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands</p><p>Manufacturer and Packaging Site:</p><p>Lilly France S.A.S, Rue du Colonel Lilly, F-67640 Fegersheim, France</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2020
Version 4
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>.يحتوي فورتيو على المادّة الفعّالة &nbsp;تيريباراتايد والتي تستخدم للمساعدة على تقوية العظام والحد من مخاطر تعرضها للكسور عن طريق تحفيز تكون العظام.</p><p>ويستخدم فورتيو في علاج هشاشة العظام لدى البالغين؛ وهو مرض يجعل العظام رفيعة وهشة. ويشيع هذا المرض بين النساء بعد انقطاع الطمث، إلا أنه قد يحدث لدى الرجال أيضا، كما يشيع بين المرضى الذين يقومون بتناول الستيرويدات القشرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم فورتيو</strong></p><ul><li>إذا كنت تعاني من حساسية لمادة التيريباراتايد أو أي من مكونات فورتيو الأخرى (المذكورة في القسم 6).</li><li>إذا كنت تعاني من زيادة مستوى الكالسيوم بالدم لديك (وجود مسبق لفرط كالسيوم الدم).</li><li>إذا كنت تعاني من قصور شديد بوظائف الكلى</li><li>إذا سبق وتم تشخيص إصابتك بسرطان العظام أو أي نوع آخر من السرطانات المنتشرة بالعظام (أي وجود تورمات ثانوية &nbsp;بالعظام لديك).</li><li>إذا كنت تعاني من بعض أمراض العظام، قم باستشارة طبيبك</li><li>&nbsp;إذا كنت تعاني من ارتفاع غير مبرر لمستوى الفوسفاتيز القلوية بالدم، مما يعني أنك قد تكون مصابا بداء باجيت في العظام (مرض يتميز بتغيرات غير طبيعية في العظام). إذا ساورك الشك في ذلك، قم باستشارة الطبيب.</li><li>إذا سبق وأن تلقيت علاجا إشعاعيا على العظام.</li><li>إذا كنت حبلى أو ترضعين.</li></ul><p><strong>تحذيرات واحتياطات&nbsp;</strong></p><p>قد يتسبب فورتيو في زيادة مستوى الكالسيوم بالدم أو البول لديك.</p><p>استشر طبيبك أو الصيدلي قبل أو خلال استخدام فورتيو:</p><ul><li>إذا كنت تعاني من غثيان مستمر، أو قيء، أو إمساك، أو انخفاض الطاقة، أو ضعف عضلي. قد تكون هذه علامات وجود الكثير من الكالسيوم في دمك.</li><li>إذا كنت تعاني أو عانيت مسبقاً من حصوات الكلى.</li><li>(إذا كنت تعاني من مشاكل في الكلى (اعتلال كلوي معتدل).</li></ul><p>قد يشكو بعض المرضى من الدوخة أو تسارع ضربات القلب بعد تلقي الجرعات الأولى من الدواء. ننصحك بحقن الجرعات الأولى من الدواء بمكان يسهل عليك الجلوس أو الاستلقاء فيه بعد الحقن مباشرة في حال شعرت بمثل هذه الأعراض.</p><p>وينبغي ألا تتعدى مدة العلاج القصوى الموصى بها؛ وهي 24 شهرا.</p><p>لا ينصح استعمال فورتيو لدى المرضى الذين لا يزالون في مراحل النمو.</p><p dir="RTL">احتمالية الإصابة بسرطان العظام. أثناء اختبار الدواء، تسبب دواء فورتيو في إصابة بعض الفئران بسرطان العظام الذي يسمى الساركوما العظمية. لم تظهر الدراسات التي أجريت على الأشخاص أن فورتيو يزيد من احتمالية الإصابة بساركوما العظام. هناك القليل من المعلومات حول احتمالية الإصابة بساركوما العظام لدى المرضى الذين يستخدمون فورتيو بعد عامين.</p><p><strong>الأطفال والمراهقون</strong></p><p>.(لا يجب <strong>ا</strong>ستخدم فورتيو من قبل الأطفال والمراهقين (الأقل من 18 عاما</p><p><strong>الأدوية الأخرى و</strong><strong>فورتيو</strong></p><p>يرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أو من المحتمل أن تتناول أية أدوية أخرى، فقد يحدث تفاعل بين بعض الأدوية (مثل عقار ديجيتاليس/ ديجوكسين؛ والذي يستخدم في علاج أمراض القلب</p><p><strong>الحمل والإرضاع</strong></p><p>لا تستخدمي فورتيو إذا كنت حبلى أو ترضعين. كما ينبغي على النساء في سن الإنجاب أن يستخدمن وسيلة فعالة لمنع الحمل أثناء استخدامهن لفورتيو. وإذا حدث حمل أثناء ذلك، يجب وقف استخدام فورتيو. كما ننصحك باستشارة طبيبك أو الصيدلي قبل البدء في تناول أي دواء</p><p><strong>القيادة واستخدام </strong><strong>الآلات</strong></p><p>قد يشعر بعض المرضى بدوخة بعد حقن فورتيو. فإذا كنت من هؤلاء المرضى، عليك أن تتجنب القيادة واستخدام الآلات حتى تشعر بتحسن</p><p><strong>:يحتوي فورتيو على الصوديوم</strong></p><p>.يحتوي هذا الدواء على أقل من 1 ميليمول&nbsp; من الصوديوم (23 ملجم) في كل جرعة، مما يعني أنه خال من الصوديوم</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم باستخدام فورتيو تماماً كما وصفه لك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p>تبلغ الجرعة الموصى بها من فورتيو 20 ميكروجرام، وتعطى مرة واحدة باليوم عن طريق الحقن تحت الجلد بمنطقة الفخذ أو البطن. وليسهل عليك تذكر مواعيد الحقن، ننصحك بحقن الدواء في نفس الموعد يوميا.</p><p>عليك أن تستمر في حقن فورتيو كل يوم كما وصفه لك طبيبك، يجب ألا تستخدم فورتيو لمدة أكثر من عامين على مدى حياتك ما لم يجد مقدم الرعاية الصحية أنك بحاجة إلى علاج أطول لأن لديك احتمالية كبيرة لكسر عظامك.</p><p>.ويمكنك حقن فورتيو مع الوجبات</p><p>.يرجى قراءة كتيب دليل الإستخدام المرفق بعبوة الدواء لمزيد من الإرشادات حول كيفية استخدام قلم فورتيو</p><p>.إبر الحقن لا ترفق مع القلم، لذا، يمكنك استخدام إبر حقن الإنسولين التابعة لمجموعة بيكتون، ديكينسون وشركاه</p><p>.عليك أن تقوم بحقن جرعة فورتيو فور استخراج القلم من الثلاجة، كما هو موصوف بدليل الإستخدام. وقم بحفظ القلم بالثلاجة مرة أخرى بعد الاستخدام مباشرة</p><p>.عليك أن تستخدم إبرة جديدة في كل عملية حقن، وتخلص منها بعد كل استخدام. ولا تقوم بحفظ القلم والإبرة متصلة به. لا تشارك قلمك فورتيو مع الآخرين</p><p>.قد ينصحك طبيبك بتناول الكالسيوم وفيتامين د بجانب فورتيو، وسوف يحدد لك الجرعة التي ستحتاج إليها يوميا</p><p>.يمكن إعطاء فورتيو مع أو بدون طعام</p><p><strong>إذا أخذت جرعة </strong><strong>من فورتيو</strong><strong> </strong><strong>أكثر مما تحتاج</strong></p><p>.إذا قمت بحقن جرعة من فورتيو أكثر مما يجب عن طريق الخطأ، قم باستشارة طبيبك أو الصيدلي</p><p>.وقد تتضمن آثار تناول جرعة مفرطة حدوث غثيان أو قيء أو دوخة أو صداع</p><p><strong>إذا نسيت أو لا تستطيع أخذ جرعة فورتيو في الوقت المعتاد </strong></p><p>.قم بأخذ الجرعة في أقرب وقت ممكن من نفس اليوم. ولا تأخذ جرعة مزدوجة لتعويض الجرعة الفائتة، كما ينبغي عدم أخذ أكثر من جرعة واحدة بنفس اليوم. ولا تحاول تعويض الجرعة الفائتة</p><p><strong>إذا توقفت عن أخذ فورتيو</strong></p><p>.إذا كنت تفكر في التوقف عن أخذ علاج فورتيو، المرجو استشارة طبيبك أو الصيدلي. سوف ينصحك طبيبك ويقرر لكم من الوقت يجب عليك الإستمرار في أخذ فورتيو</p><p>.إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، استشر طبيبك أو الصيدلي</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية الأخرى، قد يتسبب هذا الدواء في حدوث بعض الآثار الجانبية، إلا أنها لا تظهر على جميع المرضى.</p><p>الآثار الجانبية الأكثر شيوعا هي آلام بالأطراف (ترددها شائع جدا، تحدث في أكثر من مريض من كل عشر) والغثيان، الصداع والدوخة (ترددها شائع).</p><p>إذا أصبت بالدوار بعد الحقن، يجب أن تجلس أو تستلقي حتى تشعر بتحسن. إذا لم تشعر بتحسن، يجب عليك الاتصال بالطبيب قبل متابعة العلاج. تم الإبلاغ عن حالات إغماء جراء أخذ فورتيو.</p><p>إذا شعرت بعدم الإرتياح مثلا من جراء احمرار الجلد، أو الألم، أو التورم، أو الحكة، أو الكدمات، أو نزيف خفيف حول منطقة الحقن (تردد شائع)، يجب أن تختفي هذه الأعراض خلال بضعة أيام أو أسابيع٬ وإلا أخبر طبيبك في أقرب وقت ممكن.</p><p>وقد يعانى بعض المرضى من الحساسية بعد فترة وجيزة من الحقن، وتتمثل في ضيق في التنفس وتورم في الوجه والطفح الجلدي وألم في الصدر (تردد نادر). في حالات نادرة، يمكن أن تحدث تفاعلات حساسية خطيرة ربما تهدد بحياة المريض بما في ذلك الحساسية المفرطة.</p><p>تشمل الآثار الجانبية الأخرى:</p><p>آثار جانبية شائعة: تحدث لدى مريض في عشرة مرضى:</p><ul><li>&nbsp;زيادة مستويات الكوليسترول بالدم&nbsp;</li><li>&nbsp;الاكتئاب&nbsp;</li><li>&nbsp;آلام عصبية بالساق</li><li>شعور بالإغماء</li><li>اضطراب بضربات القلب</li><li>&nbsp;ضيق بالتنفس</li><li>عرق غزير&nbsp;</li><li>&nbsp;تقلصات بالعضلات</li><li>&nbsp;فقدان الطاقة</li><li>شعور بالتعب</li><li>&nbsp;ألم بالصدر&nbsp;</li><li>انخفاض ضغط الدم&nbsp;</li><li>حرقة (أسفل عظمة الصدر )</li><li>المرض (التقيؤ)&nbsp;</li><li>&nbsp;فتق الأنبوب الذي ينقل الطعام إلى معدتك&nbsp;</li><li>انخفاض الهيموجلوبين أوعدد كريات الدم الحمراء (الانيميا)&nbsp;</li><li>قلق</li></ul><p>&nbsp;</p><p>آثار جانبية غير شائعة: تحدث لدى مريض في &nbsp;كل 100 مريض:</p><ul><li>&nbsp;زيادة معدل ضربات القلب&nbsp;</li><li>&nbsp;صوت غير طبيعي للقلب&nbsp;</li><li>صعوبة التنفس</li><li>بواسير&nbsp;</li><li>&nbsp;الفقدان العرضي أو تسرب البول</li><li>&nbsp;رغبة في التبول المتكرر</li><li>&nbsp;زيادة الوزن&nbsp;</li><li>حصوات في الكلية</li><li>ألم في العضلات وألم في المفاصل .عانى بعض المرضى من تشنجات أو ألم حاد في الظهر، مما أدى إلى دخول المستشفى</li><li>&nbsp;زيادة في مستوى الكالسيوم في الدم</li><li>زيادة في مستوى حمض اليوريك في الدم&nbsp;</li><li>&nbsp;زيادة في إنزيم يسمى الفوسفاتيز القلوية&nbsp;</li></ul><p>&nbsp;</p><p>آثار جانبية نادرة : تحدث لدى مريض في كل 1000 مريض:</p><ul><li>انخفاض وظائف الكلى ، بما في ذلك الفشل الكلوي.</li><li>تورم، بشكل رئيسي في اليدين والقدمين والساقين.&nbsp;</li></ul><p dir="RTL">سرطان العظام (الساركوما العظمية): أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا كنت تعاني من ألم في عظامك ، أو ألم في أي منطقة من جسمك لا يختفي، أو أي كتل جديدة أو غير عادية أو تورم تحت الجلد يكون ملمسه رقيقًا.</p><p dir="RTL">الآثار الجانبية من التقارير التلقائية لما بعد التسويق</p><p dir="RTL">تشمل الآثار الجانبية التي تم الإبلاغ عنها منذ بداية تسويق الدواء والتي كانت بعد استعمال علاج فورتيو ما يلي:</p><ul dir="rtl"><li>ردود فعل الحساسية: تفاعلات تأقية، فرط حساسية للأدوية، وذمة وعائية، الشرى.</li></ul><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>6 إذا شعرت بأيّ آثار جانبية، تحدّث مع طبيبك أو الصيدلي. ويشمل هذا أيّ آثار جانبية محتملة غير مدرجة في هذه النشرة. یمکنك أیضا الإبلاغ عن الآثار الجانبیة مباشرة من خلال نظام الإبلاغ الوطني المدرج في القسم من خلال الإبلاغ عن الآثار الجانبیة یمکنك المساعدة في توفیر المزید من المعلومات حول سلامة ھذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ينبغي حفظ هذا الدواء بعيدا عن نظر ومتناول الأطفال.</p><p>لا تستخدم هذا الدواء &nbsp;بعد انتهاء تاريخ الصلاحية المدون على العبوة والقلم بعد&nbsp;EXP.</p><p>يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p>يجب حفظ فورتيو بالثلاجة ما بين درجة حرارة 2 و8 درجات مئوية. ويمكنك استخدام فورتيو حتى 28 يوما بعد أول مرة حقن، ما دام القلم يبقى محفوظا بالثلاجة ما بين درجة حرارة 2 و8 درجات مئوية.</p><p>لا تجمد قلم فورتيو، وتجنب حفظه قريبا من الثلج لمنع تجمده. ويجب ألا تستخدم قلم فورتيو إذا تجمد أو إذا سبق وأن تعرض للتجمد.</p><p>ينبغي التخلص من القلم بطريقة سليمة بعد مرور 28 يوما من أول حقنة، حتى وإن لم يفرغ من الدواء.</p><p>يحتوي فورتيو على محلول صاف عديم اللون. ويجب ألا تستخدم فورتيو إذا ظهرت به أية شوائب أو إذا تعكر أو تغير لون المحلول.</p><p>يجب عدم التخلص من الأدوية &nbsp;من خلال شبكة الصرف الصحي أو مع النفايات المنزلية. تساعد هذه التدابير على الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات فورتيو</strong></p><p>المادة الفعالة هي تيريباراتايد. ويحتوي كل ميليلتر من محلول الحقن على 250 ميكروجرام من مادة تيريباراتايد.</p><p>&nbsp;وتشمل المحتويات الأخرى حامض الخليك الجليدي، أسيتات الصوديوم اللامائي، مانيتول، ميتاكريسول وماء للحقن. وقد يضاف إلى ذلك حامض الهيدروكلوريك و/ أو هيدروكسيد الصوديوم لضبط مستوى الحموضة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يحتوي فورتيو على محلول صاف عديم اللون. ويتوفر الدواء في خرطوشة بداخل قلم مسبق التعبأة؛ يستخدم لمرة واحدة فقط. ويحتوي كل قلم على 2.4 مل من المحلول، ويكفي لحقن ثمان وعشرين جرعة. وتتوفر الأقلام في عبوة تحتوي على قلم واحد أو ثلاثة أقلام. قد لا تكون جميع الأحجام متوفرة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صاحب رخصة التسويق: إيلي ليلي جادة ندرلاند بابندوربسوغ 83 ، 3528 ، BJ أوتركت، هولندا.</p><p>المصنع وموقع التغليف: ليلي فرنسا إس آيه إس، طريق الكولونيل ليلي، F-67640 فيغرشيم، فرنسا.</p><p>لمزيد من المعلومات عن هذا الدواء، يرجى الاتصال بالممثل المحلي لصاحب رخصة التسويق.</p><p>شركة إيلي ليلي آند كومباني &ndash; المملكة العربية السعودية</p><p>&nbsp;ص.ب: 92120</p><p>&nbsp;الطابق 16، مبنى رقم 3074،</p><p>برج ب، أبراج العُليَّا</p><p>شارع الأمير محمد بن عبد العزيز</p><p>العُليَّا، الرياض</p><p>المملكة العربية السعودية</p><p>الخط المباشر:&nbsp; 966114617800+، +966 11 4617850</p><p>الفاكس: 966112179900+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر  2020  
النسخة 4 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FORTEO 20 micrograms/80 microliters solution for injection in pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each dose of 80 microliters contains 20 micrograms of teriparatide*.
One pre-filled pen of 2.4 mL contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL). 
*Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34 N-terminal amino acid sequence of endogenous human parathyroid hormone. 
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection. 
Colourless, clear solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FORTEO is indicated in adults.</p><p>Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). <strong>In postmenopausal women, a</strong> significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.</p><p>Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>The recommended dose of FORTEO is 20 micrograms administered once daily.</p><p>Use of FORTEO for more than 2&nbsp;years during a patient&rsquo;s lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture (see section 4.4).</p><p>Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate.</p><p>Following cessation of FORTEO therapy, patients may be continued on other osteoporosis therapies.</p><p><u>Special populations</u></p><p><em><u>Patients with renal impairment</u> </em></p><p>FORTEO must not be used in patients with severe renal impairment (see section 4.3.). In patients with moderate renal impairment, FORTEO should be used with caution. No special caution is required for patients with mild renal impairment.</p><p><strong>&nbsp;</strong><em><u>Patients with hepatic impairment</u></em></p><p>No data are available in patients with impaired hepatic function (see section 5.3). Therefore, FORTEO should be used with caution.</p><p><em><u>Paediatric population and young adults with open epiphyses:</u></em><u> </u></p><p>The safety and efficacy of FORTEO in children and adolescents less than 18 years has not been established. &nbsp;FORTEO should not be used in paediatric patients (less than 18 years), or young adults with open epiphyses.</p><p><strong>&nbsp;</strong><u>Elderly patients</u>:</p><p>Dosage adjustment based on age is not required (see section 5.2).</p><p><u>Method of administration</u></p><p>FORTEO should be administered once daily by subcutaneous injection in the thigh or abdomen.</p><p>Patients must be trained to use the proper injection techniques (see section 6.6). A user manual is also available to instruct patients on the correct use of the pen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Pregnancy and breast-feeding (see sections 4.4 and 4.6)
•	Pre-existing hypercalcaemia 
•	Severe renal impairment 
•	Metabolic bone diseases (including hyperparathyroidism and Paget’s disease of the bone) other than primary osteoporosis or glucorticoid-induced osteoporosis. 
•	Unexplained elevations of alkaline phosphatase
•	Prior external beam or implant radiation therapy to the skeleton 
•	Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number</p><p>of the administered product should be clearly recorded.</p><p><strong>Osteosarcoma</strong></p><p>An increase in the incidence of osteosarcoma (a malignant bone tumor) was observed in male and female rats treated with teriparatide. Osteosarcoma has been reported in patients treated with FORTEO in the post marketing setting; however, an increased risk of osteosarcoma has not been observed in observational studies in humans. There are limited data assessing the risk of osteosarcoma beyond 2&nbsp;years of FORTEO use<em>.</em></p><p>Avoid FORTEO use in patients with (these patients are at increased baseline risk of osteosarcoma):</p><ul><li>Open epiphyses (pediatric and young adult patients) (FORTEO is not approved in pediatric patients).</li><li>Metabolic bone diseases other than osteoporosis, including Paget&rsquo;s disease of the bone.</li><li>Bone metastases or a history of skeletal malignancies.</li><li>Prior external beam or implant radiation therapy involving the skeleton.</li><li>Hereditary disorders predisposing to osteosarcoma.</li></ul><p><u>Serum and urine calcium</u></p><p>In normocalcaemic patients, slight and transient elevations of serum calcium concentrations have been observed following teriparatide injection. Serum calcium concentrations reach a maximum between 4 and 6 hours and return to baseline by 16 to 24 hours after each dose of teriparatide. Therefore, if blood samples for serum calcium measurements are taken, this should be done at least 16 hours after the most recent FORTEO injection. Routine calcium monitoring during therapy is not required.</p><p>FORTEO may cause small increases in urinary calcium excretion, but the incidence of hypercalciuria did not differ from that in the placebo-treated patients in clinical trials.</p><p><u>Hypercalcemia</u></p><p>FORTEO has not been studied in patients with pre-existing hypercalcemia. FORTEO may cause hypercalcemia and may exacerbate hypercalcemia in patients with pre-existing hypercalcemia <em>[see Adverse Reactions (6.1, 6.3)]</em>. Avoid FORTEO in patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism.</p><p><u>Risk of Cutaneous Calcification Including Calciphylaxis</u></p><p>Serious reports of calciphylaxis and worsening of previously stable cutaneous calcification have been reported in the post-marketing setting in patients taking FORTEO. Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. Discontinue FORTEO in patients who develop calciphylaxis or worsening of previously stable cutaneous calcification.</p><p><u>Urolithiasis</u></p><p>FORTEO has not been studied in patients with active urolithiasis. Consider the risks and benefits if use in patients with active or recent urolithiasis because of the potential to exacerbate this condition.</p><p><em>&nbsp;</em><u>Orthostatic hypotension</u></p><p>In short-term clinical studies with FORTEO, isolated episodes of transient orthostatic hypotension were observed. Typically, an event began within 4 hours of dosing and spontaneously resolved within a few minutes to a few hours. When transient orthostatic hypotension occurred, it happened within the first several doses, was relieved by placing subjects in a reclining position, and did not preclude continued treatment.</p><p><u>Renal impairment</u></p><p>Caution should be exercised in patients with moderate renal impairment.</p><p><u>Younger adult population</u></p><p>Experience in the younger adult population, including premenopausal women, is limited (see section 5.1).&nbsp; Treatment should only be initiated if the benefit clearly outweighs risks in this population.</p><p>Women of childbearing potential should use effective methods of contraception during use of FORTEO. If pregnancy occurs, FORTEO should be discontinued.</p><p><u>Sodium content</u></p><p><em>&nbsp;</em>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a study of 15 healthy subjects administered digoxin daily to steady state, a single FORTEO dose did not alter the cardiac effect of digoxin. However, sporadic case reports have suggested that hypercalcaemia may predispose patients to digitalis toxicity. Because FORTEO transiently increases serum calcium, FORTEO should be used with caution in patients taking digitalis.</p><p>FORTEO has been evaluated in pharmacodynamic interaction studies with hydrochlorothiazide. No clinically significant interactions were noted.</p><p>Co-administration of raloxifene or hormone replacement therapy with FORTEO did not alter the effects of FORTEO on serum or urine calcium or on clinical adverse events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in females</u></p><p>Women of childbearing potential should use effective methods of contraception during use of FORTEO.&nbsp; If pregnancy occurs, FORTEO should be discontinued.&nbsp;</p><p><u>Pregnancy</u></p><p>FORTEO is contraindicated for use during pregnancy (see section 4.3).</p><p><u>Breast-feeding</u></p><p>FORTEO is contraindicated for use during breast-feeding. It is not known whether teriparatide is excreted in human milk.</p><p><u>Fertility</u></p><p>Studies in rabbits have shown reproductive toxicity (see section 5.3). The effect of teriparatide on human foetal development has not been studied. The potential risk for humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FORTEO has no or negligible influence on the ability to drive and use machines. Transient, orthostatic hypotension or dizziness was observed in some patients. These patients should refrain from driving or the use of machines until symptoms have subsided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions in patients treated with FORTEO are nausea, pain in limb, headache and dizziness.&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Of patients in the teriparatide trials, 82.8&nbsp;% of the FORTEO patients and 84.5&nbsp;% of the placebo patients reported at least 1 adverse event.</p><p>The adverse reactions associated with the use of teriparatide in osteoporosis clinical trials and post-marketing exposure are summarised in the table below. The following convention has been used for the classification of the adverse reactions: very common (&ge; 1/10), common (&ge; 1/100 to &lt;1/10), uncommon (&ge; 1/1,000 to &lt;1/100), rare (&ge; 1/10,000 to &lt;1/1,000) very rare (&lt;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p><p><em>Common</em>: Anaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorder</strong></p><p><em>Rare</em>: Anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p><p><em>Common</em>: Hypercholesterolaemia</p><p><em>Uncommon</em>: Hypercalcaemia greater than 2.76&nbsp;mmol/L, hyperuricemia</p><p><em>Rare</em>: Hypercalcaemia greater than 3.25&nbsp;mmol/L</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p><p><em>Common</em>: Anxiety, Depression</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p><p><em>Common</em>: Dizziness, headache, sciatica, syncope</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p><p><em>Common</em>: Vertigo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p><p><em>Common</em>: Palpitations</p><p><em>Uncommon</em>: Tachycardia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p><p><em>Common</em>: Hypotension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p><em>Common</em>: Dyspnoea</p><p><em>Uncommon:</em> Emphysema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p><em>Common</em>: Nausea, vomiting<u>,</u> hiatus hernia, gastroesophageal reflux disease</p><p><em>Uncommon</em>: Haemorrhoids</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p><p><em>Common</em>: Sweating increased</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p><p><em>Very common</em>: Pain in limb</p><p><em>Common</em>: Muscle cramps</p><p><em>Uncommon</em>: Myalgia, arthralgia, back cramp/pain*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p><p><em>Uncommon</em>: Urinary incontinence, polyuria, micturition urgency, nephrolithiasis</p><p><em>Rare</em>:<em> </em><em>&nbsp;</em>Renal failure/impairment</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p><p><em>Common:</em> Fatigue, chest pain, asthenia, mild and transient injection site events, including pain, swelling, erythema, localised bruising, pruritis and minor bleeding at injection site.</p><p><em>Uncommon</em>: Injection site erythema, injection site reaction</p><p><em>Rare</em>: Possible allergic events soon after injection: acute dyspnoea, oro/facial oedema, generalised urticaria, chest pain, oedema (mainly peripheral).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p><p><em>Uncommon</em>: Weight increased, cardiac murmur, alkaline phosphatase increase</p></td></tr></tbody></table><p>*Serious cases of back cramp or pain have been reported within minutes of the injection.</p><p><u>Description of selected adverse reactions</u></p><p>In clinical trials the following reactions were reported at a &ge; 1% difference in frequency from placebo: vertigo, nausea, pain in limb, dizziness, depression, dyspnoea.</p><p>FORTEO increases serum uric acid concentrations.&nbsp; In clinical trials, 2.8% of FORTEO patients had serum uric acid concentrations above the upper limit of normal compared with 0.7% of placebo patients.&nbsp; However, the hyperuricemia did not result in an increase in gout, arthralgia, or urolithiasis.</p><p>In a large clinical trial, antibodies that cross-reacted with teriparatide were detected in 2.8% of women receiving FORTEO.&nbsp; Generally, antibodies were first detected following 12 months of treatment and diminished after withdrawal of therapy.&nbsp; There was no evidence of hypersensitivity reactions, allergic reactions, effects on serum calcium, or effects on Bone Mineral Density BMD response.</p><p>Adverse Reactions from Postmarketing Spontaneous Reports</p><p>Adverse events reported since market introduction that were temporally related to FORTEO therapy include the following:</p><ul><li>Allergic Reactions: Anaphylactic reactions, drug hypersensitivity, angioedema, and urticaria.</li></ul><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed here.</p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance and Drug Safety Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Signs and symptoms</u></p><p>FORTEO has been administered in single doses of up to 100 micrograms and in repeated doses of up to 60&nbsp;micrograms/day for 6 weeks.</p><p>The effects of overdose that might be expected include delayed hypercalcaemia<strong> </strong>and risk of orthostatic hypotension. Nausea, vomiting, dizziness, and headache can also occur.</p><p><em>&nbsp;</em><u>Overdose experience based on post-marketing spontaneous reports:</u></p><p>In post-marketing spontaneous reports, there have been cases of medication error where the entire contents (up to 800 mcg) (40 times the recommended dose) of the FORTEO prefilled pen have been administered as a single dose.&nbsp;Transient events reported have included nausea, weakness/lethargy and hypotension. No fatalities associated with overdose have been reported.&nbsp;Additional signs, symptoms, and complications of FORTEO overdosage may include a delayed hypercalcemic effect, vomiting, dizziness, and headache.</p><p><u>Overdose management:</u></p><p>There is no specific antidote for FORTEO. Treatment of suspected overdose should include transitory discontinuation of FORTEO, monitoring of serum calcium, and implementation of appropriate supportive measures, such as hydration.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: Calcium homeostasis, parathyroid hormones and analogues, ATC code: H05 AA02.</p><p><em>&nbsp;</em><u>Mechanism of action: </u></p><p>Endogenous 84-amino-acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney. FORTEO (rhPTH(1-34)) is the active fragment (1-34) of endogenous human parathyroid hormone. Physiological actions of PTH include stimulation of bone formation by direct effects on bone forming cells (osteoblasts) indirectly increasing the intestinal absorption of calcium and increasing the tubular re-absorption of calcium and excretion of phosphate by the kidney.</p><p><u>Pharmacodynamic effects</u></p><p>FORTEO is a bone formation agent to treat osteoporosis. The skeletal effects of FORTEO depend upon the pattern of systemic exposure. Once-daily administration of FORTEO increases apposition of new bone on trabecular and cortical bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity.</p><p><u>Clinical efficacy </u></p><p><em>Risk Factors</em></p><p>Independent risk factors, for example, low BMD, age, the existence of previous fracture, family history of hip fractures, high bone turnover and low body mass index should be considered in order to identify women and men at increased risk of osteoporotic fractures who could benefit from treatment.</p><p>Premenopausal women with glucocorticoid-induced osteoporosis should be considered at high risk for fracture if they have a prevalent fracture or a combination of risk factors that place them at high risk for fracture (e.g., low bone density [e.g., T score &le;&minus;2], sustained high dose glucocorticoid therapy [e.g., &ge;7.5 mg/day for at least 6 months], high underlying disease activity, low sex steroid levels).</p><p><em>Postmenopausal osteoporosis</em></p><p>The <u>pivotal study</u> included 1637 postmenopausal women (mean age 69.5 years). At baseline, ninety percent of the patients had one or more vertebral fractures, and on average, vertebral BMD was 0.82 g/cm<sup>2</sup> (equivalent to a T-score = - 2.6). All patients were offered 1000&nbsp;mg calcium per day and at least 400&nbsp;IU vitamin D per day. Results from up to 24 months (median: 19 months) treatment with FORTEO demonstrate statistically significant fracture reduction<em> </em>(Table 1). To prevent one or more new vertebral fractures, 11 women had to be treated for a median of 19 months.</p><p><strong>Table 1</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:667px"><tbody><tr><td colspan="4" style="vertical-align:top; width:664px"><p>Fracture Incidence in Postmenopausal Women:<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N&nbsp;=&nbsp;544) (%)</p></td><td style="vertical-align:top"><p>FORTEO</p><p>(N&nbsp;=&nbsp;541) (%)</p></td><td style="vertical-align:top; width:160px"><p>Relative risk<br />(95% CI)<br />vs. placebo</p></td></tr><tr><td style="vertical-align:top"><p>New vertebral fracture (&ge;1)<sup> a</sup></p></td><td style="vertical-align:top"><p>14.3</p></td><td style="vertical-align:top"><p>5.0<sup> </sup><sup>b</sup></p></td><td style="vertical-align:top; width:160px"><p>0.35</p><p>(0.22, 0.55)</p></td></tr><tr><td style="vertical-align:top"><p>Multiple vertebral fractures (&ge;2)<sup> a</sup></p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>1.1<sup> </sup><sup>b</sup></p></td><td style="vertical-align:top; width:160px"><p>0.23</p><p>(0.09, 0.60)</p></td></tr><tr><td style="vertical-align:top"><p>Non-vertebral fragility fractures<sup> c</sup></p></td><td style="vertical-align:top"><p>5.5%</p></td><td style="vertical-align:top"><p>2.6% <sup>d</sup></p></td><td style="vertical-align:top; width:160px"><p>0.47<br />(0.25, 0.87)</p></td></tr><tr><td style="vertical-align:top"><p>Major non-vertebral fragility fractures<sup>c</sup> (hip, radius, humerus, ribs and pelvis)</p></td><td style="vertical-align:top"><p>3.9%</p></td><td style="vertical-align:top"><p>1.5% <sup>d</sup></p></td><td style="vertical-align:top; width:160px"><p>0.38<br />(0.17, 0.86)</p></td></tr></tbody></table><p>Abbreviations:&nbsp; N = number of patients randomly assigned to each treatment group; CI = Confidence Interval.</p><p><sup>&nbsp;</sup>&nbsp;<sup>a </sup>The incidence of vertebral fractures was assessed in 448 placebo and 444 FORTEO patients who had baseline and follow-up spine radiographs.</p><p><sup>&nbsp;b </sup>p&pound;0.001 compared with placebo</p><p><sup>c </sup>A significant reduction in the incidence of hip fractures has not been demonstrated</p><p><sup>d</sup> p&pound;0.025 compared with placebo.</p><p>After 19 months (median) treatment, bone mineral density (BMD) had increased in the lumbar spine and total hip, respectively, by 9% and 4% compared with placebo (p&lt;0.001).</p><p>Post-treatment management: Following treatment with FORTEO, 1262 postmenopausal women from the pivotal trial enrolled in a post-treatment follow-up study. The primary objective of the study was to collect safety data of FORTEO. During this observational period, other osteoporosis treatments were allowed and additional assessment of vertebral fractures was performed.</p><p>During a median of 18 months following discontinuation of FORTEO, there was a 41% reduction (p=0.004) compared with placebo in the number of patients with a minimum of one new vertebral fracture.</p><p>In an open-label study, 503 postmenopausal women with severe osteoporosis and a fragility fracture within the previous 3 years (83% had received previous osteoporosis therapy) were treated with FORTEO for up to 24 months. At 24 months, the mean increase from baseline in lumbar spine, total hip and femoral neck BMD was 10.5%, 2.6% and 3.9% respectively. The mean increase in BMD from 18 to 24 months was 1.4%, 1.2%, and 1.6% at the lumbar spine, total hip and femoral neck, respectively.</p><p>A 24-month, randomized, double-blind, comparator-controlled Phase 4 study included 1,360 postmenopausal women with established osteoporosis. 680 subjects were randomised to Forteo and 680 subjects were randomised to oral risedronate 35 mg/week. At baseline, the women had a mean age of 72.1 years and a median of 2 prevalent vertebral fractures; 57.9% of patients had received previous bisphosphonate therapy and 18.8% took concomitant glucocorticoids during the study. 1,013 (74.5%) patients completed the 24-month follow-up. The mean (median) cumulative dose of glucocorticoid was 474.3 (66.2) mg in the teriparatide arm and 898.0 (100.0) mg in the risedronate arm. The mean (median) vitamin D intake for the teriparatide arm was 1433 IU/day (1400 IU/day) and for the risedronate arm was 1191 IU/day (900 IU/day). For those subjects who had baseline and follow-up spine radiographs, the incidence of new vertebral fractures was 28/516 (5.4%) in Forteo- and 64/533 (12.0%) in risedronate-treated patients, relative risk (95% CI) = 0.44 (0.29-0.68), P&lt;0.0001. The cumulative incidence of pooled clinical fractures (clinical vertebral and non vertebral fractures) was 4.8% in Forteo and 9.8% in risedronate-treated patients, hazard ratio (95% CI) = 0.48 (0.32-0.74), P=0.0009.</p><p><em>Male osteoporosis&nbsp; </em></p><p>437 patients (mean age 58.7 years) were enrolled in a clinical trial for men with hypogonadal (defined as low morning free testosterone or an elevated FSH or LH) or idiopathic osteoporosis. Baseline spinal and femoral neck bone mineral density mean T-scores were -2.2 and -2.1, respectively.&nbsp; At baseline, 35% of patients had a vertebral fracture and 59% had a non-vertebral fracture.</p><p>All patients were offered 1000 mg calcium per day and at least 400 IU vitamin D per day. Lumbar spine BMD significantly increased by 3 months. After 12 months, BMD had increased in the lumbar spine and total hip by 5% and 1%, respectively, compared with placebo<strong>. </strong>However, no significant effect on fracture rates was demonstrated.</p><p><em>Glucocorticoid-induced osteoporosis</em></p><p>The efficacy of FORTEO in men and women (N=428) receiving sustained systemic glucocorticoid therapy (equivalent to 5 mg or greater of prednisone for at least 3 months) was demonstrated in the 18-month primary phase of a 36 month, randomised, double-blind, comparator-controlled study (alendronate 10 mg/day). Twenty-eight percent of patients had one or more radiographic vertebral fractures at baseline. All patients were offered 1000 mg calcium per day and 800 IU vitamin D per day.</p><p>This study included postmenopausal women (N=277), premenopausal women (N=67), and men (N=83). At baseline, the postmenopausal women had a mean age of 61 years, mean lumbar spine BMD T score of &minus;2.7, median prednisone equivalent dose of 7.5 mg/day, and 34% had one or more radiographic vertebral fractures; premenopausal women had a mean age of 37 years, mean lumbar spine BMD T score of &minus;2.5, median prednisone equivalent dose of 10 mg/day, and 9% had one or more radiographic vertebral fractures; and men had a mean age of 57 years, mean lumbar spine BMD T score of &minus;2.2, median prednisone equivalent dose of 10 mg/day, and 24% had one or more radiographic vertebral fractures.</p><p>Sixty-nine percent of patients completed the 18-month primary phase.&nbsp; At the 18 month endpoint, FORTEO significantly increased lumbar spine BMD (7.2%) compared with alendronate (3.4%) (p&lt;0.001). FORTEO increased BMD at the total hip (3.6%) compared with alendronate (2.2%) (p&lt;0.01), as well as at the femoral neck (3.7%) compared with alendronate (2.1%) (p&lt;0.05). In patients treated with teriparatide, lumbar spine, total hip and femoral neck BMD increased between 18 and 24 months by an additional 1.7%, 0.9%, and 0.4%, respectively.</p><p>At 36 months, analysis of spinal X-rays from 169 alendronate patients and 173 FORTEO patients showed that 13 patients in the alendronate group (7.7%) had experienced a new vertebral fracture compared with 3 patients in the FORTEO group (1.7%) (p=0.01). In addition, 15 of 214 patients in the alendronate group (7.0%) had experienced a non-vertebral fracture compared with 16&nbsp;of 214 patients in the FORTEO group (7.5%) (p=0.84).</p><p>In premenopausal women, the increase in BMD from baseline to 18 month endpoint was significantly greater in the FORTEO group compared with the alendronate group at the lumbar spine (4.2% versus &minus;1.9%; p&lt;0.001) and total hip (3.8% versus 0.9%; p=0.005).&nbsp; However, no significant effect on fracture rates was demonstrated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distribution</p><p>&nbsp;The volume of distribution is approximately 1.7&nbsp;L/kg. The half-life of FORTEO<sup> </sup>is approximately 1 hour when administered subcutaneously, which reflects the time required for absorption from the injection site.</p><p><u>Biostransformation</u></p><p>No metabolism or excretion studies have been performed with FORTEO<sup> </sup>but the peripheral metabolism of parathyroid hormone is believed to occur predominantly in liver and kidney.</p><p><u>Elimination</u><em> </em></p><p>FORTEO<sup> </sup>is eliminated through hepatic and extra-hepatic clearance (approximately 62&nbsp;L/hr in women and 94&nbsp;L/hr in men).</p><p><em>&nbsp;</em><u>Elderly </u></p><p>No differences in FORTEO<sup> </sup>pharmacokinetics were detected with regard to age (range 31 to 85 years). Dosage adjustment based on age is not required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Teriparatide was not genotoxic in a standard battery of tests. It produced no teratogenic effects in rats, mice or rabbits. There were no important effects observed in pregnant rats or mice administered teriparatide at daily doses of 30 to 1000 &micro;g/kg. However, fetal resorption and reduced litter size occurred in pregnant rabbits administered daily doses of 3 to 100 &micro;g/kg. The embryotoxicity observed in rabbits may be related to their much greater sensitivity to the effects of PTH on blood ionised calcium compared with rodents.</p><p>Rats treated with near-life time daily injections had dose-dependent exaggerated bone formation and increased incidence of osteosarcoma most probably due to an epigenetic mechanism. Teriparatide did not increase the incidence of any other type of neoplasia in rats. Due to the differences in bone physiology in rats and humans, the clinical relevance of these findings is probably minor. No bone tumours were observed in ovariectomised monkeys treated for 18 months or during a 3-year follow-up period after treatment cessation. In addition, no osteosarcomas have been observed in clinical trials or during the post treatment follow-up study.</p><p>Animal studies have shown that severely reduced hepatic blood flow decreases exposure of PTH to the principal cleavage system (Kupffer cells) and consequently clearance of PTH(1-84).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glacial acetic acid&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;0.41mg/ml</p><p>Sodium acetate (anhydrous)&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.....0.10mg/ml</p><p>Mannitol&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;...45.4mg/ml</p><p>Metacresol&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.3mg/ml</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
Chemical, physical and microbiological in-use stability has been demonstrated for 28 days at 2-8°C. Once opened, the product may be stored for a maximum of 28 days at 2°C to 8°C. Other in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C) at all times. The pen should be returned to the refrigerator immediately after use. Do not freeze.</p><p>Do not store the injection device with the needle attached.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2.4&nbsp;mL solution in cartridge (siliconised Type I glass) with a plunger (halobutyl rubber), disc seal (polyisoprene/bromobutyl rubber laminate)/aluminium assembled into a disposable pen.</p><p>FORTEO is available in pack sizes of 1 or 3 pens. Each pen contains 28 doses of 20 micrograms (per 80 microliters).</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FORTEO is supplied in a pre-filled pen. Each pen should be used by only one patient. A new, sterile needle must be used for every injection. Each FORTEO pack is provided with a user manual that fully describes the use of the pen. No needles are supplied with the product. The device can be used with insulin pen injection needles. After each injection, the FORTEO pen should be returned to the refrigerator.</p><p>FORTEO should not be used if the solution is cloudy, coloured or contains particles.</p><p>Please also refer to the user manual for instructions on how to use the pen.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
16 November 2020
Version 4

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>